Janux Therapeutics Names William Go as Chief Medical Officer
Event summary
- William Go, M.D., Ph.D., appointed Chief Medical Officer of Janux Therapeutics effective January 26, 2026.
- Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who is leaving to pursue other opportunities.
- Dr. Go brings over 20 years of hematology and oncology experience, including leadership roles at A2 Biotherapeutics, Kite Pharma, and Amgen.
- Janux Therapeutics is advancing two clinical candidates, JANX007 and JANX008, targeting PSMA and EGFR respectively.
- The company is also developing additional programs under its TRACTr, TRACIr, and ARM platforms.
The big picture
Janux Therapeutics is strengthening its leadership team at a critical juncture as it advances its pipeline of novel immunotherapies. The appointment of William Go, M.D., Ph.D., as Chief Medical Officer underscores the company's focus on scaling its clinical and regulatory operations. Dr. Go's extensive experience in hematology and oncology, particularly in leading programs from early clinical development through pivotal trials and global regulatory approvals, positions Janux to tackle important clinical challenges in oncology. The move reflects broader industry trends towards specialized leadership in biotech companies aiming to bring innovative therapies to market.
What we're watching
- Pipeline Progression
- How Janux Therapeutics will advance its TRACTr, TRACIr, and ARM platforms under Dr. Go's leadership.
- Regulatory Strategy
- Whether Dr. Go's experience in global regulatory approvals will accelerate Janux's clinical and regulatory operations.
- Leadership Transition
- The impact of Dr. Go's appointment on Janux's ability to scale its clinical and regulatory efforts effectively.
Related topics